We noticed that a lack of diagnostic criteria was increasingly being mentioned in the published literature on post-SSRI sexual dysfunction (PSSD). The condition was being described as difficult to diagnose because there was no commonly accepted definition.
At the same time, a number of new websites and online discussions were appearing, many of which seemed to have slightly different interpretations of what is and isn’t PSSD.
Although the condition had already been well characterized in the literature, particularly in relation to the hallmark features of decreased genital and orgasmic sensation, there seemed to be a need for a formal set of criteria. We decided to write a new paper.
RxISK was the first group to publish peer-reviewed literature on persistent sexual dysfunction after the use of isotretinoin, a medication used in the treatment of acne. We have also described commonalities between post-SSRI sexual dysfunction, post-finasteride syndrome and post-retinoid sexual dysfunction. It therefore seemed logical that we should include all three conditions as well as persistent genital arousal disorder which presents with an almost mirror image of genital arousal or irritability rather than numbness.
We are pleased to announce the online publication of “Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin“.
You can view and download the pre-press version on the above link. There are a few small formatting errors from the publisher which will hopefully be corrected in the printed version when it comes out, but the article is still perfectly legible. [Now updated with printed version.]
It provides diagnostic criteria for:
Writing the paper, getting it published, and being able to make it freely available has required a lot of work. It’s also been our most ambitious collaboration to date with 37 authors.
The journal would normally charge $27.50 USD to access the full paper unless you are a subscriber. Another option is to pay €1250 for open access which makes it free for everyone to view and download. We contacted all of the authors and suggested that if we split the open access cost equally, each person would only have to pay a relatively small amount. While many of the authors agreed to contribute, there was a shortfall of around €300 which RxISK has covered.
Feel free to share the paper with anyone who might be interested.
There’s also an international list of doctors who are familiar with the condition. At the moment, this list contains 16 doctors across 9 countries, but we need your help to find more.
If you’ve had experience with a doctor who might be suitable, could you ask if they would be interested in being on our list. If they are, please provide us with an email address so we can contact them. Alternatively, they can send us a message via our contact page.